CHARM Therapeutics
CHARM Therapeutics is a biotechnology company focused on developing next-generation precision oncology treatments, specifically targeting acute myeloid leukemia (AML). Utilizing its proprietary AI-driven drug discovery platform, DragonFold, CHARM is advancing a novel menin inhibitor designed to overcome resistance mutations that limit the efficacy of first-generation therapies. The company's innovative approach aims to provide more durable and effective treatment options for AML patients, with clinical development of its lead candidate expected to commence in early 2026. Based in Cambridge and London, CHARM is supported by a strong syndicate of international investors.
Leadership & Board
- Current Number of Employees
- 29
- Current LinkedIn Followers
- 13,386
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $80M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $80M
- Latest Funding Round
- Series B
- Post-Money Valuation
- ―
Company Momentum Positive
CHARM Therapeutics LinkedIn following is increasing, signaling rising market interest, while its workforce size remains relatively unchanged.
Employee Trend
CHARM Therapeutics had 29 employees as of October 12, 2026. The number of employees decreased by 1 (3.33%) week-over-week.
Social Trend
CHARM Therapeutics had 13,386 followers as of October 12, 2026. The number of followers increased by 34 (0.25%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Sep 02, 2025 | Series B | $80.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Khosla Ventures | Series B |
| OrbiMed | Series B |
| SR One | Series B |
| F-Prime | Series B |
| NVIDIA | Series B |
| New Enterprise Associates | Series B |
Similar Companies
A snapshot of private companies similar to CHARM Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis
